Where to buy KPV Australia: what should a research purchaser verify first?
When a laboratory asks where to buy KPV Australia, the first checks are identity documentation, lot linkage and whether the material is local stock with tracked dispatch. A website name is not an identity test. KPV is three residues long; inverted sequences, dipeptide deletions and lysine-modified analogues can be sold under the same letters if nobody reads the mass spectrum. Request the CoA for the exact lot that will be shipped, not a representative chromatogram from another batch. Confirm that the CoA lists Lys-Pro-Val, a molecular formula consistent with the free tripeptide (C16H30N4O4) or a stated salt, and an observed mass matching the theoretical monoisotopic mass of approximately 342.23 Da, typically [M+H]+ near m/z 343.2. Ask whether net peptide content is reported separately from gross vial mass, because trifluoroacetate or acetate counter-ions and residual moisture change the peptide fraction of a lyophilised solid. Australian procurement also turns on chain-of-custody paperwork: the packing list must carry the same lot number as the CoA. Overseas drop-shipping without lot-level records leaves the receiving laboratory unable to reconcile the vial. Prefer suppliers who publish HPLC conditions (column, gradient, detection wavelength) and MS ionisation mode. Record specification limits for chromatographic purity and related substances so goods-in inspection has a written acceptance criterion. If the supplier declines to share method parameters or lot-matched spectra before dispatch, treat that refusal as a disqualifying documentation gap rather than a negotiable extra.
How is KPV chemically defined as α-MSH(11–13) Lys-Pro-Val?
KPV is defined chemically as the C-terminal tripeptide of α-melanocyte-stimulating hormone, residues 11–13 (Lys-Pro-Val). That definition is a sequence assignment. Elliott and co-workers treated MSH 11–13 KPV as a discrete peptide alongside intact α-MSH and adrenocorticotropic hormone in keratinocyte-cell work, which anchors the three-letter code to a specified melanocortin fragment (PMID:15102092). Reviews of α-MSH biochemistry locate related tripeptides at the C-terminus and discuss the motif separately from the full tridecapeptide pharmacophore (PMID:18612139; PMID:21222263). For purchasing laboratories, “KPV” on a label must map to H-Lys-Pro-Val-OH unless a terminal modification is declared. Acetylated, amidated, D-amino-acid or cyclic variants are different entities with different exact masses and retention times. The free peptide formula is C16H30N4O4. A CoA that omits termini, counter-ion and observed m/z leaves identity incomplete. The lysine side-chain amine is a reactive handle. Songok and colleagues described reductive glycoalkylation of that residue as a structural modification of KPV, producing mass shifts that would fail an unmodified-KPV identity test if they dominated the lot (PMID:29953505). Unexpected glycosyl or alkyl increments are out-of-specification unless a conjugate was ordered. Dimeric (CKPV)2 incorporates cysteine chemistry and is not equivalent to monomeric Lys-Pro-Val (PMID:16413580). Require the sequence, terminal status and theoretical mass on the same page as the lot number. Catalogue headings such as melanocortin fragment are not substitutes for residue-level structure, because several distinct sequences share that family name and will not match the KPV mass.
Which HPLC–MS identity and purity fields belong on a KPV CoA?
A KPV CoA should let an independent chemist reconstruct identity and purity assignment. It should state the reversed-phase column (phase, dimensions, particle size), mobile phases, gradient, flow rate, column temperature, sample volume, detection wavelength and integration events for area-percent purity. Lys-Pro-Val has no aromatic side chain, so 280 nm is not a credible purity channel; low-UV detection at 210–220 nm is required for the peptide-bond chromophore. Query any CoA that quotes 280 nm data for KPV. Electrospray ionisation of the free tripeptide should yield a predominant [M+H]+ ion near m/z 343.2; sodium or potassium adducts must be annotated. A match to monoisotopic mass supports C16H30N4O4. Tandem MS, if supplied, should show fragments consistent with Lys–Pro and Pro–Val cleavage (b2, y1, y2). Without MS, the CoA is only a chromatographic fingerprint. Area-percent is not mass-fraction peptide. List related substances with relative retention time. Diode-array peak-purity indices are weak for this non-aromatic tripeptide and do not replace MS. State whether trifluoroacetic or formic acid was the ion-pair reagent, because retention, peak shape and residual counter-ion all change. Net peptide content, water by Karl Fischer, and residual TFA or acetate complete mass balance so lots are compared as milligrams of peptide, not powder. If amino-acid analysis is provided, the Lys:Pro:Val ratio should be approximately 1:1:1; large deviations suggest a different sequence or a co-eluting impurity that UV area-percent missed.
How do laboratories distinguish authentic KPV from analogues and modified lysine species?
Short peptides produce a related-substance map that tests whether a lot is authentic KPV. Deletion sequences (Lys-Pro, Pro-Val, Lys-Val), residual amino acids and inversion isomers are plausible synthetic impurities. Proline-containing peptides can form diketopiperazines; a cyclic Lys-Pro species would differ in mass and retention from linear KPV. Incomplete lysine deprotection leaves protecting-group mass increments that ESI-MS should flag. Lysine modification creates new chemical entities. Reductive glycoalkylation of the lysine residue of KPV yields glycosylated analogues distinguished by carbohydrate mass and altered chromatography (PMID:29953505). If unmodified KPV was ordered, those species belong in the related-substance table. Dimeric (CKPV)2 incorporates cysteine and a duplicated motif; it is not Lys-Pro-Val and will not match C16H30N4O4 (PMID:16413580). Longer melanocortin fragments that merely contain a KPV subsequence are not KPV. CoA sequence text must be the structure that was synthesised. Counter-ion and hydrate forms change net content without changing sequence. Trifluoroacetate and acetate salts are different quantification materials even when HPLC purity matches. Laboratories comparing Australian quotes should normalise to net peptide content and a stated salt, otherwise a lower list price may reflect a heavier counter-ion. Archive the related-substances chromatogram with the lot, not only a single purity number. Solid-phase synthesis of a tripeptide is short, which can tempt inadequate in-process control. The purchaser’s defence is orthogonal MS plus a named related-substance list, not a shorter production cycle claimed by the vendor. This distinction is a purchasing specification, not a naming preference.
What batch documentation should accompany an Australian KPV research order?
Once identity criteria are set, the remaining risk is documentary: can the vial be traced to the chromatogram? An Australian research order should carry the same identifiers on the CoA, vial label, packing list and invoice—lot number, optional vial code, product code encoding the sequence, and the reported purity and net content. If identifiers disagree, hold the material until a corrected record is issued. Local stock and tracked dispatch shorten chain of custody. Material held in Australia can be allocated to a named lot before dispatch, and the tracking reference is filed beside the CoA. Ask for the lot number on outer consignment documents so receiving staff need not open primary packs at goods-in. Retain the CoA in the laboratory quality system with the HPLC method print-out when a separate batch report is supplied. Write specification limits into the purchase order: chromatographic purity, mass-match window, appearance of the lyophilised solid, and water if required. Limits must be lot-specific; representative chromatograms from a previous campaign do not release the lot received. Research-only terms belong on the same paperwork. KPV as a laboratory reagent is not a registered therapeutic good; receiving organisations should confine it to in vitro or analytical workflows. Missing lot-matched spectra or mismatched labels are sufficient reason to choose another Australian supplier. A complete file also includes the safety data sheet for the lyophilised solid and a statement of residual counter-ion, which workplace-safety reviewers will request even though those pages do not prove sequence identity.
How should Australian laboratories compare KPV suppliers before purchasing?
A structured comparison beats a single purity figure. For each Australian supplier, tabulate sequence on the CoA, theoretical and observed mass, HPLC purity and wavelength, ion-pair reagent, net peptide content, counter-ion, water, related-substance listing, lot-number format, and local-stock status. Score only evidenced items. A supplier who cannot produce a lot-matched CoA before dispatch is not comparable on price. Method transparency discriminates. Two 98% values are not equivalent if one was measured at 215 nm on a formic-acid gradient with MS confirmation and the other is an unspecified 280 nm trace. Request system suitability: main-peak retention window, tailing factor and replicate-chromatogram precision. For a weakly UV-active tripeptide, sample-introduction precision and blank subtraction affect the purity digit more than they would for an aromatic peptide. Ask whether the SKU is H-Lys-Pro-Val-OH, whether lysine-modified or dimeric products share similar names, and how mix-ups are prevented. Literature treats KPV as α-MSH(11–13) and (CKPV)2 as a different molecule; procurement should do the same (PMID:15102092; PMID:16413580). Compare minimum vial size, ability to reserve further vials from the same lot, lead time from local stock, tracked dispatch, and whether chromatogram, MS spectrum and integration table are included. Prefer complete lot documentation. After receipt, check goods against the purchase-order specification and archive the CoA with the laboratory notebook. That is the operational answer to where to buy KPV Australia: the supplier who can prove the vial is Lys-Pro-Val of the stated lot.
Order Kpv with documentation
If this guide helped you evaluate Kpv for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.
Open the Kpv card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.
Frequently asked questions
Is a catalogue name enough to identify a KPV research lot?
No. Identity requires the sequence H-Lys-Pro-Val-OH (or a declared modification), a mass consistent with C16H30N4O4, and a lot-matched CoA. Analogues, dimers such as (CKPV)2 and lysine-modified species can share a similar sales name. Demand HPLC–MS data for the shipped lot before purchase.
What HPLC detection wavelength is appropriate for KPV purity?
KPV has no Phe, Tyr or Trp, so 280 nm does not measure the peptide. Purity should be reported at low UV, typically 210–220 nm, with the wavelength stated on the CoA. A 280 nm purity figure for this tripeptide is not interpretable and should be queried with the supplier.
How do I match an Australian shipment to its CoA?
Compare lot number, product code and net content across vial label, packing list, invoice and CoA. Local stock with tracked dispatch helps because the allocated lot is known before the consignment moves. Any mismatch is a hold at goods-in until the supplier issues a corrected record.
Why does net peptide content matter more than list price per vial?
Lyophilised solids include counter-ion and water. Two vials of equal gross mass can contain different amounts of Lys-Pro-Val if TFA versus acetate loads differ. Normalise quotes to net peptide content and the stated salt so Australian supplier prices are chemically comparable.
Are KPV and α-MSH the same material?
No. KPV is only residues 11–13 of α-MSH. The parent tridecapeptide has a different mass, chromatogram and specification. CoA text should give the tripeptide structure, not a family name. Reviews that discuss related tripeptides still treat KPV as a distinct chemical entity (PMID:18612139).
What should be refused at goods-in for a KPV lot?
Refuse lots lacking a lot-matched CoA, MS identity, or consistent labelling. Also refuse material whose observed m/z does not fit Lys-Pro-Val or whose HPLC method uses 280 nm as the sole purity channel. Documentation gaps are sufficient grounds to reject a research peptide delivery.
References
- PMID:15102092 — alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells — J Invest Dermatol — 2004
- PMID:16413580 — Inhibitory effects of the peptide (CKPV)2 on endotoxin-induced host reactions — J Surg Res — 2006
- PMID:18612139 — Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases — Endocr Rev — 2008
- PMID:21222263 — Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore — Adv Exp Med Biol — 2010
- PMID:29953505 — Structural modification of the tripeptide KPV by reductive "glycoalkylation" of the lysine residue — PLoS One — 2018
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
